- Home
- GOSS vs ADCT Comparison
GOSS vs ADCT Comparison
Compare GOSS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ADCT
- Stock Information
- Founded
- GOSS 2015
- ADCT 2011
- Country
- GOSS United States
- ADCT Switzerland
- Employees
- GOSS N/A
- ADCT N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- ADCT Health Care
- Exchange
- GOSS Nasdaq
- ADCT Nasdaq
- Market Cap
- GOSS 262.5M
- ADCT 241.0M
- IPO Year
- GOSS 2019
- ADCT 2020
- Fundamental
- Price
- GOSS $1.23
- ADCT $2.71
- Analyst Decision
- GOSS Strong Buy
- ADCT Strong Buy
- Analyst Count
- GOSS 4
- ADCT 6
- Target Price
- GOSS $7.75
- ADCT $7.80
- AVG Volume (30 Days)
- GOSS 2.6M
- ADCT 1.0M
- Earning Date
- GOSS 08-11-2025
- ADCT 08-05-2025
- Dividend Yield
- GOSS N/A
- ADCT N/A
- EPS Growth
- GOSS N/A
- ADCT N/A
- EPS
- GOSS N/A
- ADCT N/A
- Revenue
- GOSS $124,590,000.00
- ADCT $75,817,000.00
- Revenue This Year
- GOSS N/A
- ADCT $10.65
- Revenue Next Year
- GOSS $91.14
- ADCT $15.05
- P/E Ratio
- GOSS N/A
- ADCT N/A
- Revenue Growth
- GOSS N/A
- ADCT 10.49
- 52 Week Low
- GOSS $0.66
- ADCT $1.05
- 52 Week High
- GOSS $1.55
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- GOSS 54.09
- ADCT 46.56
- Support Level
- GOSS $1.25
- ADCT $2.59
- Resistance Level
- GOSS $1.44
- ADCT $2.98
- Average True Range (ATR)
- GOSS 0.10
- ADCT 0.31
- MACD
- GOSS -0.00
- ADCT -0.15
- Stochastic Oscillator
- GOSS 41.67
- ADCT 8.70
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).